NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ('NRx Pharmaceuticals'), a clinical-stage biopharmaceutical company, today, 18th June, announced that the Company has appointed Dr. Dennis McBride to its Board of Directors.

Dr. McBride has significant experience in Neuroscience, Medical and Information Technology and digital therapeutics.

'I am delighted to welcome Dennis to the Board of NRx. His unique background in both Neuroscience and Medical Technology will be an important asset to the company as we seek to develop more advanced treatments for patients,' said Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx. 'I have worked with Dennis previously on a highly successful digital therapeutic and know the quality he brings to our company.'

'I am proud to join the Board of NRx at such an exciting time for the company - the opportunities have never been greater in Neuroscience to advance and improve novel therapies,' commented Dr. McBride. 'I look forward to using my experience to help advance its strategy and further the development of NRx's impressive pipeline of CNS products and leading its initiative in digital therapeutics.'